NCT06315101Completed
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
A Real-world Study of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 18 Mar 2024
Brief summary (registry, in English)
This study aims to assess the effectiveness and safety of lenvatinib plus Chinese Herbal Medicine (CHM) for patients with uHCC in China.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 142 (actual)
- First submitted
- 7 Mar 2024
- Start date
- 1 Sept 2023
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Guangzhou University of Chinese Medicine
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06315101
What you commit to
- Study type: Observational
- Participants enrolled: 142
- From 1 Sept 2023 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- patients with other primary tumors
- patients who had only one visit record and were lost to follow-up or refused follow-up
- patients with any other factors affecting study data collection
Who the study is looking for
- at least 18 years old
- histologically confirmed HCC unsuitable for resection
- lenvatinib as first- or second-line therapy
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Guangzhou University of Chinese Medicine Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.